deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT01000727

The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial (SOLID-TIMI 52)

A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE).

Sponsor: GlaxoSmithKline

Conditions Acute Coronary Syndrome
Interventions Darapladib 160 mg Placebo Standard Therapy
Updated 13 times since 2017 Last updated: Jul 12, 2017 Started: Dec 1, 2009 Primary completion: Apr 1, 2014 Completion: Apr 24, 2014
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01000727, this PHASE3 trial focuses on Acute Coronary Syndrome and remains completed. Sponsored by GlaxoSmithKline, it has been updated 13 times since 2009, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Sep 2017 · 7 months · monthly snapshot~Sep 2017 – ~Jun 2018 · 9 months · monthly snapshot~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Nov 2025 · 2 months · monthly snapshot~Nov 2025 – ~Feb 2026 · 3 months · monthly snapshot~Jan 2026 – present · 3 months · monthly snapshot~Feb 2026 – present · 2 months · monthly snapshot~Feb 2026 – present · 2 months · monthly snapshot~Mar 2026 – present · 43 days · monthly snapshot

Change History

13 versions recorded

  1. Mar 2026 — Present [monthly]

    Completed PHASE3

  2. Feb 2026 — Present [monthly]

    Completed PHASE3

  3. Feb 2026 — Present [monthly]

    Completed PHASE3

  4. Jan 2026 — Present [monthly]

    Completed PHASE3

  5. Nov 2025 — Feb 2026 [monthly]

    Completed PHASE3

▶ Show 8 earlier versions

  1. Sep 2025 — Nov 2025 [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  6. Sep 2017 — Jun 2018 [monthly]

    Completed PHASE3

  7. Feb 2017 — Sep 2017 [monthly]

    Completed PHASE3

  8. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Dec 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
  • The TIMI Study Group
Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

's-Hertogenbosch, Netherlands , Aalborg, Denmark , Aalst, Belgium , Aarhus, Denmark , Adelaide, Australia , Ahmedabad, India , Airdrie, United Kingdom , Ajax, Canada , Albany, United States , Alberton, South Africa and 695 more locations